Please assess the completion status of the following clinical trial:

Trial Title: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese male or female infants ≥2 months to ≤6 months at the time of consent.~* Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.~Exclusion Criteria:~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)~* Major known congenital malformation or serious chronic disorder.~* History of microbiologically proven invasive disease caused by S pneumoniae.~* Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- 20-valent pneumococcal conjugate vaccine (subcutaneous) (Type: EXPERIMENTAL): 20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
- 13-valent pneumococcal conjugate vaccine (subcutaneous) (Type: ACTIVE_COMPARATOR): 13-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
- 20-valent pneumococcal conjugate vaccine (intramuscular) (Type: EXPERIMENTAL): 20-valent pneumococcal conjugate vaccine administered by intramuscular injection (IM)

Based on this trial design, predict the completion outcome and termination type (if applicable).